From the Research
Aripiprazole may be considered as a potential treatment option for cannabis use disorder, particularly in individuals with co-occurring mental health conditions, but its use should be approached with caution and as part of a comprehensive treatment plan, as evidenced by a study published in 2013 1. The use of aripiprazole for cannabis use disorder is not FDA-approved, and the current evidence is limited to small studies and case reports. However, some research suggests that aripiprazole may help reduce cannabis cravings and use in certain individuals, particularly those with co-occurring mental health conditions like schizophrenia or bipolar disorder.
- Aripiprazole is an atypical antipsychotic that works by modulating dopamine and serotonin systems, which are involved in addiction and reward pathways affected by cannabis.
- If prescribed, treatment typically starts at 2-5mg daily, potentially increasing to 10-15mg daily based on response and tolerability.
- Common side effects include nausea, headache, insomnia, and restlessness.
- Treatment would likely be part of a comprehensive approach including therapy, counseling, and support groups.
- A recent systematic review published in 2025 2 highlights the importance of considering the potential risks and benefits of medicinal cannabis on mental health, and aripiprazole may be a viable alternative for some individuals.
- Another study published in 2023 3 found an association between cannabis use and bipolar disorder, emphasizing the need for caution when using cannabis or considering treatments like aripiprazole.
- Ultimately, anyone considering aripiprazole for cannabis use disorder should consult with a psychiatrist or addiction specialist to discuss potential benefits, risks, and alternative treatments, as other medications like N-acetylcysteine or gabapentin might be more appropriate depending on individual circumstances.